Renard, who is living with Alzheimer’s disease, arm in arm with RJ, his care partner on a sofa
Clipboard showing brain with early Alzheimer’s disease

Diagnosing Alzheimer’s disease

Alzheimer’s disease is a type of progressive brain disease that causes problems with:

  • memory
  • language
  • thinking

Who is LEQEMBI for?

LEQEMBI is for people in the early stages of Alzheimer's disease, which are known as:

Mild cognitive impairment (MCI) due to Alzheimer’s disease

This is when symptoms like forgetfulness and confusion are very mild and may not get in the way of daily life.

Mild Alzheimer’s dementia
 

This is when symptoms like trouble keeping track of bills and difficulty with familiar tasks start to get in the way of daily life.

Do not receive LEQEMBI if you have serious allergic reactions to lecanemab-irmb or to any of the ingredients in LEQEMBI.

RJ putting his arms around Renard, who is living with Alzheimer’s disease, in a supermarket

Your healthcare provider will confirm if
LEQEMBI is right for you

Your healthcare provider may use tests designed to evaluate your brain health and help figure out if your symptoms are due to early Alzheimer's disease. They'll explain what tests you need to make sure LEQEMBI is right for you.

Tests you should know about

Your healthcare provider will use one of these tests to check for amyloid brain plaque. That's because LEQEMBI is thought to work by targeting harmful amyloid proteins and reducing existing amyloid brain plaque.

Cerebrospinal fluid (CSF) test

Cerebrospinal fluid (CSF) test

This test takes samples of the fluid around your brain and spinal cord.

Amyloid positron emission tomography (PET) scan

Amyloid positron emission tomography
(PET) scan

This test uses a special machine that takes pictures of your brain.

Blood-based biomarker (BBBM) test

Blood-based biomarker (BBBM) test*

This test measures a blood sample to check for amyloid brain plaque.

Information about LEQEMBI infusions

*BBBMs are currently being studied as a newer alternative test to look for amyloid proteins.

Woman in office from Eisai Patient Support smiling and talking on headset
Woman from Eisai Patient Support smiling and talking on headset
Eisai Patient Support logo

We can help you determine your insurance coverage and learn where to access your medication.

Find out more

LEQEMBI clinical study results

In a large, 18-month study:

Treatment with LEQEMBI was proven to slow the progression of early Alzheimer's disease, helping people remember, solve problems, and complete daily activities for longer.

Who was included in the study?

People in a study for LEQEMBI
1,795 men and women*
Participants in a study for LEQEMBI were between the ages of 50 and 90
Ages 50 to 90
Participants in a study for LEQEMBI had MCI or mild dementia due to Alzheimer’s disease
With mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease
Participants in a study for LEQEMBI were from different ethnic and racial backgrounds
From different ethnic and racial backgrounds

*The study was divided into 2 groups. One group took LEQEMBI (898 people) and the other group did not take LEQEMBI (897 people).

Kay, who is living with Alzheimer’s disease, arm in arm with Jennyfer, her care partner

LEQEMBI safety

While taking LEQEMBI, your healthcare provider will monitor your progress on treatment. They’ll also watch for any side effects. One potential side effect is Amyloid Related Imaging Abnormalities or “ARIA.”
Your healthcare provider will monitor you for ARIA with a magnetic resonance imaging (MRI) scan before starting treatment and before your 5th, 7th, and 14th infusions.

What to keep in mind about ARIA symptoms

ARIA is most commonly seen as temporary swelling in areas of the brain that usually resolves over time. Some people may also have small spots of bleeding in or on the surface of the brain and, infrequently, larger areas of bleeding in the brain can occur. Most people with this type of swelling in the brain do not get symptoms—however, some people may have symptoms, such as:

Increased risk of ARIA in ApoE4 carriers

Understanding the role your genes play

Some people have a genetic risk factor that may increase the risk of ARIA. Talk to your healthcare provider about testing to see if you have this risk factor.

Tips for care partners

Tips for care partners

An important step in staying on top of ARIA is making sure the whole healthcare team knows your loved one is taking LEQEMBI. Consider mentioning it at any upcoming appointments or adding a note if they use an online patient portal.

Talk to your healthcare provider if you have any questions.

Information about LEQEMBI infusions

Learn what to do before, during, and
after each infusion.

Find tips
Hand holding phone with information and support for LEQEMBI

Get help passing the time at LEQEMBI appointments

Discover LEQEMBI Companion